FDA Cosmetic Compliance
CIRG provides FDA Consulting for cosmetic companies navigating MoCRA, facility registration, product listing, labeling, safety substantiation, and inspection readiness. We help manufacturers, processors, and responsible persons understand their obligations and identify compliance gaps before they create regulatory problems. Our approach focuses on practical execution, accurate records, and current FDA requirements. Whether entering the U.S. market or strengthening an existing program, CIRG helps companies build a clearer, more defensible cosmetic compliance strategy.
Understanding MoCRA and FDA Cosmetic Requirements
The Modernization of Cosmetics Regulation Act of 2022 significantly expanded FDA authority over cosmetic products. MoCRA added requirements for facility registration, product listing, serious adverse event reporting, safety substantiation, and manufacturing oversight. FDA also gained new records-access and mandatory-recall authorities under specified conditions. Companies must first determine whether their products meet FDA’s definition of a cosmetic. Claims can change a product’s regulatory status and may cause FDA to regulate it as a drug or another product type. CIRG provides FDA Consulting to help cosmetic companies understand these requirements and establish practical compliance systems. We assess regulatory responsibilities, documentation, reporting processes, and potential compliance gaps. Our approach helps manufacturers, processors, and responsible persons focus on requirements that apply to their operations. Strong MoCRA compliance begins with correct product classification and clear regulatory accountability.
Cosmetic Facility Registration and Biennial Renewal
MoCRA requires manufacturers and processors of covered cosmetic products to register applicable facilities with FDA. Registered facilities must renew their registration every two years. FDA also requires updates when certain registration information changes. Some qualifying small businesses may receive exemptions, although important exceptions apply. Products used around the eye, injected products, internally used cosmetics, and certain long-lasting appearance products may fall outside small-business exemptions. FDA can also suspend a facility registration under serious public-health circumstances specified by law. CIRG provides FDA Consulting to help companies determine registration obligations and prepare accurate submissions. We can review facility information, manufacturing responsibilities, exemptions, and renewal requirements before filing. Accurate registration matters because errors can create unnecessary regulatory questions or disrupt market access. CIRG helps companies maintain a controlled process for initial registration, updates, and recurring biennial renewal obligations.
Cosmetic Product Listing and Annual Updates
MoCRA requires the responsible person to list each covered cosmetic product marketed in the United States with FDA. Product listings include information such as product categories and ingredients. The responsible person must also provide required updates annually. FDA defines the responsible person as the manufacturer, packer, or distributor whose name appears on the product label. Certain small businesses may qualify for exemptions, subject to important statutory exceptions. Product listing does not mean that FDA has approved the cosmetic. Companies still remain responsible for safety, labeling, claims, and other applicable requirements. CIRG provides FDA Consulting to help businesses organize product data and prepare accurate listing submissions. We also help companies develop processes for annual review and updates. A controlled listing system becomes especially important when companies manage multiple brands, formulations, contract manufacturers, or frequent product changes across the U.S. market.
Responsible Person Requirements and Serious Adverse Event Reporting
MoCRA assigns important responsibilities to the cosmetic product’s responsible person. FDA defines this party as the manufacturer, packer, or distributor identified on the product label. A responsible person must report serious adverse events associated with U.S. cosmetic use within 15 business days. The initial submission must include a copy of the product label. New medical or other relevant information received within one year also requires submission within 15 business days. Companies must maintain required adverse event records, generally for six years. Certain qualifying small businesses may use a three-year retention period. CIRG provides FDA Consulting to help establish intake, assessment, documentation, escalation, and reporting procedures. We can also evaluate whether personnel understand serious adverse event criteria and reporting timelines. A reliable system helps prevent late reports, incomplete investigations, and avoidable FDA concerns during inspections.
Safety Substantiation and Cosmetic Recordkeeping
MoCRA requires responsible persons to ensure adequate safety substantiation for cosmetic products and maintain supporting records. FDA does not mandate one specific test for every cosmetic or ingredient. Instead, companies may rely on appropriate tests, studies, research, analyses, and other scientifically sound information. Qualified experts should be able to support a reasonable certainty that the cosmetic is safe under intended use. Animal testing is not required for marketing a cosmetic product. Companies should maintain organized safety records that support ingredients, formulations, exposure, and product use. CIRG provides FDA Consulting to help businesses evaluate whether their safety documentation supports regulatory expectations. We also review record controls, supporting evidence, and internal responsibility for maintaining substantiation. Strong documentation matters because FDA now has broader records-access authority in certain circumstances. Safety conclusions should be defensible, current, and supported by reliable scientific information.
Cosmetic Labeling and Claims Compliance
Cosmetic labeling must comply with the FD&C Act, Fair Packaging and Labeling Act, and applicable FDA regulations. Required information can include product identity, net quantity, business information, ingredients, and necessary warnings. Labels must present required information prominently and in terms consumers can understand. Ingredient declarations generally follow descending order of predominance, subject to regulatory exceptions. Claims deserve equal attention because they can change how FDA regulates the product. A claim to treat disease or affect body structure or function can move a product into drug regulation. FDA does not preapprove ordinary cosmetic labeling before marketing. CIRG provides FDA Consulting to review labels, claims, packaging, websites, and promotional materials for regulatory risk. We help companies identify wording that may create unintended drug claims or misleading representations. Careful review can prevent misbranding issues before products reach the U.S. market.
Cosmetic GMP and FDA Inspection Readiness
MoCRA directs FDA to establish Good Manufacturing Practice regulations for facilities that manufacture or process cosmetic products. FDA currently maintains cosmetic GMP guidance and continues to identify GMP rulemaking as a MoCRA requirement. Companies should therefore build manufacturing controls that support product quality, cleanliness, traceability, and reliable records. FDA also has expanded inspection and records-access authority for cosmetics under MoCRA. Inspection readiness should address complaints, safety information, manufacturing records, raw materials, distribution, and other relevant documentation. CIRG provides FDA Consulting to help companies assess manufacturing practices before FDA identifies weaknesses. We review procedures, records, personnel practices, sanitation, controls, and management oversight from an inspection perspective. A proactive program helps companies prepare for evolving FDA requirements while strengthening daily operations. Cosmetic manufacturers should also monitor FDA rulemaking because future GMP regulations may create additional specific obligations.
Dermal Fillers and Aesthetic Medical Devices
Dermal fillers serve cosmetic and aesthetic purposes, but FDA regulates them as medical devices, not cosmetic products. FDA describes dermal fillers as injectable medical device implants used to create a smoother or fuller appearance. Approved uses vary by product and may include facial wrinkles, lips, cheeks, chin, hands, or other specified indications. Manufacturers therefore should not treat dermal fillers as MoCRA cosmetic products. They must address the medical device regulatory pathway, applicable quality requirements, labeling, clinical evidence, and postmarket obligations. CIRG provides FDA Consulting for companies operating across both cosmetic and aesthetic medical device markets. We help determine the correct regulatory framework before companies build registration, quality, or submission strategies. Correct classification matters because cosmetic rules and medical device requirements differ substantially. CIRG can help companies keep these requirements clearly separated while supporting a coordinated U.S. market strategy.
Dermal Fillers Are Medical Devices Subject to QMSR and ISO 13485
Although dermal fillers are used for cosmetic and aesthetic purposes, FDA regulates them as medical devices. Manufacturers of finished dermal filler devices must therefore comply with the Quality Management System Regulation (QMSR) under 21 CFR Part 820 when applicable. QMSR became effective on February 2, 2026, and incorporates ISO 13485:2016 by reference as the foundation for medical device quality management systems.
That means dermal filler manufacturers should address medical device quality requirements such as risk management, design and development, supplier controls, production controls, CAPA, complaints, and postmarket activities. CIRG provides FDA Consulting to help aesthetic device manufacturers prepare for QMSR compliance, ISO 13485 alignment, and FDA inspection readiness.
FDA Cosmetic Compliance Support
CIRG provides FDA Consulting for cosmetic manufacturers, processors, responsible persons, importers, and companies entering the U.S. market. Support can include MoCRA assessments, facility registration, product listing, labeling review, safety substantiation, adverse event systems, and inspection readiness. We can address one specific regulatory problem or evaluate a broader compliance program. Each engagement focuses on practical implementation and documented evidence rather than unnecessary paperwork. CIRG also helps companies distinguish cosmetics from products that FDA regulates as drugs or medical devices. This distinction becomes particularly important when claims, ingredients, intended use, or product design create overlapping regulatory issues. Our objective is to identify compliance gaps before they delay market access or attract regulatory attention. Companies receive clear priorities and practical recommendations based on their products and operations. Effective FDA Consulting should make compliance easier to manage, understand, and defend.
Cosmetic Compliance Through an FDA Inspection Perspective
Cosmetic compliance becomes more practical when companies view their systems through an FDA inspection perspective. FDA can examine records, manufacturing conditions, complaints, safety information, and other evidence within its statutory authority. MoCRA expanded that authority and strengthened FDA oversight of the cosmetics industry. An investigator may follow a complaint into adverse event records, safety substantiation, manufacturing controls, distribution information, or related documentation. CIRG FDA Consulting focuses on these connections when evaluating cosmetic compliance programs. We examine whether written procedures match actual practices and whether records support management decisions. Particular attention goes to missing documentation, weak complaint handling, unsupported safety conclusions, labeling risks, and inconsistent manufacturing controls. This approach helps companies find weaknesses before FDA does. Inspection-focused preparation also gives management a clearer understanding of how individual compliance problems can develop into broader regulatory concerns requiring corrective action or remediation.
Engage CIRG for FDA Cosmetic Compliance
CIRG provides FDA Consulting for cosmetic companies that need practical support with MoCRA, facility registration, product listing, labeling, safety substantiation, adverse event reporting, and inspection readiness. We also assist companies working with aesthetic products that may fall under medical device requirements, including dermal fillers.
Our approach focuses on identifying regulatory gaps before they affect market access or trigger FDA concerns. CIRG can support targeted projects or broader compliance assessments, depending on your needs. Whether you are entering the U.S. market, updating an existing compliance program, or preparing for FDA scrutiny, CIRG can help clarify the requirements and strengthen your regulatory position.
Contact CIRG to discuss your cosmetic compliance needs and determine the right next step.